0000950170-24-009991.txt : 20240201
0000950170-24-009991.hdr.sgml : 20240201
20240201215835
ACCESSION NUMBER: 0000950170-24-009991
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240201
DATE AS OF CHANGE: 20240201
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 24588653
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: REED ELIZABETH E
CENTRAL INDEX KEY: 0001283303
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: 9050 CAMINO SANTA FE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
144
1
primary_doc.xml
144
0001283303
XXXXXXXX
LIVE
0001438533
Travere Therapeutics, Inc.
001-36257
3611 Valley Centre Dr.
Suite 300
San Diego
CA
92130
888-969-7879
Elizabeth E. Reed
Officer
Common
Morgan Stanley Smith Barney
3 Edison Drive
Alpharetta
GA
30005
2174
18547.85
75145831
02/01/2024
NASDAQ
Common
01/31/2024
Restricted Stock Unit Vesting
Issuer
N
2174
01/31/2024
Compensation
N
Elizabeth E. Reed
3611 Valley Centre Drive
Suite 300
San Diego
CA
92130
Common
01/23/2024
2062
18475.52
Elizabeth E. Reed
3611 Valley Centre Drive
Suite 300
San Diego
CA
92130
Common
02/01/2024
2590
22947.40
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
02/01/2024
/s/ Elizabeth E. Reed